VASOCIDIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vasocidin, and what generic alternatives are available?
Vasocidin is a drug marketed by Novartis and is included in two NDAs.
The generic ingredient in VASOCIDIN is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
Summary for VASOCIDIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 8 |
Patent Applications: | 17 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VASOCIDIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for VASOCIDIN
US Patents and Regulatory Information for VASOCIDIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | VASOCIDIN | prednisolone acetate; sulfacetamide sodium | OINTMENT;OPHTHALMIC | 088791-001 | Oct 5, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | VASOCIDIN | prednisolone sodium phosphate; sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 018988-001 | Aug 26, 1988 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |